Probiotic supplementation (VSL#3) significantly increased fecal TLR4 agonist activity without improving disease activity in children with juvenile idiopathic arthritis, and conservative analysis suggested lower clinical response rates with VSL#3 compared to placebo.
Key Findings
Results
Probiotic supplementation with VSL#3 did not improve clinical disease activity compared to placebo in children with JIA.
The primary clinical endpoint was the proportion achieving an ACR Pedi 30 response at 3 months.
ACR Pedi 30 response rates were 47% with VSL#3 versus 63% with placebo (p = 0.33).
Conservative worst-case assumptions for missing data suggested lower response rates with VSL#3 (36% vs 68%; p = 0.03).
The trial was a multicentre randomized, double-blind, placebo-controlled design with 1:1 allocation.
44 children were enrolled between September 2017 and July 2022.
Fecal TLR4 agonist activity was measured from stool samples collected at baseline and month 3.
The increase in TLR4 agonist activity occurred in the VSL#3 group but not the placebo group.
TLR4 agonists are pro-inflammatory microbial stimuli, suggesting increased exposure to such stimuli with probiotic use.
This finding occurred without detectable changes in microbial community diversity.
Results
Gut microbiota diversity remained unchanged following 3 months of probiotic supplementation.
Gut microbiota composition was assessed from stool samples collected at baseline and month 3.
No significant differences in microbiota diversity were detected between VSL#3 and placebo groups.
The probiotic supplementation lasted 3 months in addition to standard therapy.
This indicates that VSL#3 modified microbial innate immune signalling without altering overall microbial community structure.
Results
Intestinal permeability was not significantly altered by probiotic supplementation.
Intestinal permeability was assessed from stool and serum samples at baseline and month 3.
No significant differences in intestinal permeability were observed between the VSL#3 and placebo groups.
This measure was included as part of the assessment of host-microbiota immune interactions.
Results
Systemic cytokine levels did not differ significantly between the VSL#3 and placebo groups.
Serum cytokine levels were measured at baseline and month 3.
No significant changes in systemic cytokine profiles were detected with probiotic supplementation.
This finding suggests that VSL#3 did not produce detectable systemic immune modulation despite local changes in TLR4 agonist activity.
Methods
The study targeted children with oligoarticular or RF-negative polyarticular juvenile idiopathic arthritis receiving standard therapy.
Participants had oligoarticular or RF-negative polyarticular JIA subtypes.
VSL#3 or placebo was administered for 3 months as an add-on to standard therapy.
The trial was conducted across multiple centres (multicentre design).
The study was double-blind and placebo-controlled with a 1:1 randomization ratio.
The trial was named PERMAJI and enrolled participants between September 2017 and July 2022.
Conclusions
The authors conclude that probiotic supplementation can modify microbial innate immune signalling without detectable changes in microbial community diversity and may increase exposure to pro-inflammatory microbial stimuli.
The increase in TLR4 agonist activity represents modification of microbial innate immune signalling.
The authors note this may represent increased exposure to pro-inflammatory microbial stimuli in early-life autoimmune disease.
The findings underscore 'the need for careful evaluation of microbiome-targeted therapies in paediatric autoimmune disorders.'
The results 'highlight the complexity of host-microbiota immune interactions.'
What This Means
This research looked at whether giving children with juvenile idiopathic arthritis (JIA) — a form of childhood arthritis — a probiotic supplement called VSL#3 for three months could help improve their symptoms and influence how their gut bacteria interact with their immune system. The study enrolled 44 children and randomly assigned them to receive either VSL#3 or a placebo (dummy supplement) on top of their usual arthritis treatment. The main question was whether more children in the probiotic group would show meaningful improvement in their arthritis activity after three months.
The results showed that the probiotic did not help children's arthritis symptoms more than the placebo. About 47% of children taking VSL#3 showed clinical improvement compared to 63% in the placebo group, though this difference was not statistically significant in the main analysis. When researchers accounted for missing data in a more conservative way, the probiotic group actually appeared to do worse. On the biological side, the probiotic did cause one notable change: it increased the levels of molecules in the stool that activate a specific immune sensor called TLR4, which is associated with triggering inflammation. However, the overall makeup of gut bacteria, the leakiness of the gut lining, and levels of inflammation markers in the blood were all unchanged.
This research suggests that taking probiotics in the context of childhood autoimmune disease is more complicated than simply 'more good bacteria equals better health.' The probiotic increased signals that could promote inflammation without improving the disease or changing the broader bacterial community in the gut. These findings highlight the importance of carefully testing microbiome-targeted treatments — like probiotics — in children with autoimmune conditions before recommending them, as the effects on the immune system may not always be beneficial.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.